KE dipeptide; Lysylglutamate; Lys-Glu; L-lysyl-L-glutamic acid; Thymus bioregulator · Evidence-based safety and harm-reduction overview.
| Also known as | KE dipeptide; Lysylglutamate; Lys-Glu; L-lysyl-L-glutamic acid; Thymus bioregulator |
| Category | Peptide (research chemical) |
| Structure | Synthetic dipeptide: L-lysyl-L-glutamic acid (Lys-Glu) |
| Developer | Prof. Vladimir Khavinson, St. Petersburg Institute of Bioregulation and Gerontology |
| Primary research area | Thymic involution, immune senescence, epigenetic gene reactivation |
| Animal lifespan data | 20-40% mean lifespan extension reported in CBA mouse models; not established in humans |
| Human trial status | No registered human clinical trials on ClinicalTrials.gov; available human data is observational and Russian-sourced |
| Mechanism class | Proposed epigenetic/chromatin regulator via minor-groove DNA binding; not a receptor agonist or hormone |
| US legal status | No FDA approval. Not approved by the EMA or any Western regulatory authority. In the United States and EU, Vilon is classified as an unapproved investigational compound and is supplied by research vendors for in vitro and laboratory use only, not for human consumption. It has been used in clinical settings in Russia for decades, where it occupies a regulatory category as a peptide bioregulator, but this status does not confer approval elsewhere. No ClinicalTrials.gov-registered human trials exist. |
Vilon is a synthetic dipeptide bioregulator composed of lysine and glutamic acid (Lys-Glu). It was developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology as part of a broader class of short peptide bioregulators originally derived from thymic tissue. It is hypothesized to act epigenetically rather than through classical receptor-ligand signaling, and research has focused primarily on immune senescence, thymic involution, and aging biology. Evidence in humans is very limited; the compound remains at a preclinical and early observational research stage in Western medicine.
Vilon is proposed to act via direct interaction with DNA rather than through membrane receptors. In vitro studies indicate the KE dipeptide binds to specific nucleotide sequences (GCGC in nucleosomal DNA; TCGA in B-form DNA), occupying the minor groove and forming hydrogen bonds with bases and the phosphate backbone. This binding is associated with deheterochromatinization - partial unrolling of facultative heterochromatin - which is hypothesized to reactivate silenced genes, particularly ribosomal RNA genes. Separately, cell culture studies in aged lymphocytes have shown stimulation of thymocyte proliferation, T-helper cell activation, and suppression of apoptosis. The mechanistic picture is plausible but derives largely from in vitro and animal work; human pharmacodynamic data are absent.
Vilon emerged from Soviet-era military-funded research programs in the 1970s-1980s investigating peptide extracts of endocrine and immune organs for potential geroprotective and stress-resistance applications. Khavinson and colleagues developed a library of short synthetic dipeptides intended to replicate the bioactive signals of organ-specific peptide fractions. Vilon was characterized as the thymic fraction analog. Over subsequent decades, the St. Petersburg Institute published extensively in Russian-language biogerontology journals and selected Western outlets on this compound class. Western scientific engagement has been limited, partly due to language barriers and the absence of large randomized controlled trials meeting contemporary standards. The compound is now commercially distributed internationally by peptide research vendors, though it retains no regulatory approval outside Russia.
Research on Vilon falls into three categories. First, animal lifespan studies: long-term administration in CBA mice from 6 months of age through natural death reportedly produced 20-40% mean lifespan extension and suppression of spontaneous tumor development; these findings originate from the Khavinson laboratory and have not been independently replicated in Western preclinical programs. Second, mechanistic in vitro work: a 2004 PubMed-indexed study (PMID 15105581) demonstrated chromatin reactivation and restoration of ribosomal gene expression in aged lymphocytes, providing the primary molecular rationale for the compound. Third, human observational data: limited Russian clinical reports describe immune parameter changes in elderly subjects, including increases in thymic proliferative indices, but these are observational, lack blinded controls, and have not been published in peer-reviewed Western journals with adequate methodology sections. No Western randomized controlled trials exist. The overall evidence base is preclinical and mechanistic, with human efficacy entirely unestablished by current standards.
Published animal studies used chronic subcutaneous administration over months at weight-based doses not directly translatable to humans. Russian clinical observational literature references subcutaneous injection protocols, but these are not accessible as peer-reviewed Western publications with methodology sufficient to extract reliable ranges. No human dose-finding, pharmacokinetic, or dose-response trials appear in ClinicalTrials.gov or major Western databases. Any dosing figures circulating in online communities are not grounded in controlled human evidence. This field is informational only and does not constitute a protocol; anyone considering research applications should consult a qualified clinician and operate within applicable regulatory frameworks.
This is general research/context information, not medical advice or a recommended protocol.
No controlled human data exists on Vilon in combination with other compounds. In Russian biogerontology research, Vilon is sometimes described alongside other Khavinson-class peptide bioregulators (Epithalon, Cortexin, Thymalin) as part of organ-system-specific cycling protocols, but these protocols are not substantiated by randomized trial evidence. Any stacking approach remains purely speculative and unsupported by peer-reviewed human data.
Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.
Get tested with Ulta Lab Tests →No. Both are Khavinson-class dipeptide bioregulators from the same research program, but they are distinct compounds. Epithalon (Ala-Glu-Asp-Gly) is a tetrapeptide associated with pineal and telomerase research. Vilon (Lys-Glu) is a dipeptide developed as a thymic bioregulator with a focus on immune senescence. They have different amino acid sequences, different tissue origins in the original extract-based research, and different mechanistic profiles.
In aging cells, some genes that were active in youth become silenced as DNA is compacted into tightly packed heterochromatin. The 2004 PMID 15105581 study reported that Vilon's KE dipeptide binds to specific DNA sequences in aged lymphocytes and induces partial unrolling of this compacted chromatin (deheterochromatinization), restoring expression of previously silenced genes including ribosomal RNA genes. This finding is mechanistically interesting but derives from in vitro work; its functional significance in living humans has not been established.
The 20-40% mean lifespan extension figures come from long-term administration studies in CBA mice conducted at the Khavinson laboratory. These are animal-only findings and cannot be extrapolated to human longevity. Independent replication by Western research groups using modern methodology has not been published. The data is preliminary and rodent-specific.
This entry does not provide dosing guidance. No controlled human dose-finding or pharmacokinetic study has been conducted and published in peer-reviewed Western literature. Any dose figures in circulation are not grounded in validated human evidence. Anyone considering research applications should consult a qualified clinician.
Vilon is not FDA-approved and cannot be legally marketed as a drug or dietary supplement for human use in the United States. It is sold by research chemical vendors as a laboratory compound for in vitro research use only. Purchasing for personal human consumption exists in a legal gray area and carries regulatory risk. The legal landscape for unapproved peptides can change; users should verify current status with legal counsel.
No human drug-interaction studies have been conducted or published. The immune-modulatory activity observed in preclinical settings raises a theoretical concern about concurrent use with immunosuppressants or immune-modulating therapies, but this is speculative. Clinician consultation is essential before any use alongside prescription medications.
Medical & legal disclaimer. This site is for informational and harm-reduction purposes only. It is not medical advice and is not a substitute for a licensed healthcare professional. The compounds discussed are largely not approved by the FDA for human use and many are sold strictly as research chemicals 'not for human consumption.' Nothing here is an endorsement to purchase, possess, or use any substance. Laws vary by jurisdiction. Always consult a qualified physician and follow the law where you live.
Some links on this page may be affiliate links. If you buy through them we may earn a commission at no extra cost to you. This never changes the safety information we publish.